Management of Endometrial Carcinoma

Adjuvant Therapy

Once surgical staging is complete, the focus shifts to adjuvant therapy to reduce the risk of recurrence. This treatment is tailored to the specific stage and the histology of the tumor.

Radiation Therapy

For patients diagnosed with Stage II disease, Radiation Therapy (RT) is often required. This may include External Beam Radiation Therapy (EBRT) and/or vaginal brachytherapy. Radiation is also utilized in advanced stages (III–IV) in combination with other modalities.

Systemic Therapy

Systemic therapy is reserved for specific risk profiles and advanced stages:

• Stage I: Treatment is determined by specific risk factors, such as tumor grade and the presence of LVSI.
• Stage III–IV: Management typically involves systemic therapy combined with EBRT and/or vaginal brachytherapy.

Modern systemic therapy is increasingly driven by molecular analysis. For instance, in recurrent or metastatic disease, clinicians may use biomarker-directed therapies, such as immunotherapy for tumors with mismatch repair deficiency (dMMR) or targeted agents for specific gene fusions.

Fertility-Sparing Options and Ovarian Preservation

For a specific subset of patients, the goal of treatment may extend beyond cancer eradication to include the preservation of reproductive function.

Criteria for Fertility-Sparing Management

Fertility-sparing options are considered for select premenopausal patients with Grade 1 (well-differentiated) endometrioid adenocarcinoma that is limited to the endometrium. To qualify, several strict criteria must be met:

1. Histology: Must be Grade 1 endometrioid adenocarcinoma, ideally confirmed by expert pathology review via hysteroscopy or D&C.
2. Imaging: No suspicious findings on MRI or ultrasound.
3. Molecular Profile: Absence of p53 abnormality, mismatch repair (MMR) deficiency, and Lymphovascular Space Invasion (LVSI) is preferred.
4. Genetic Risk: No family history of Lynch syndrome or ovarian cancer.
5. Consultation: Prior consultation with a fertility expert is required.

Treatment Protocols

The primary treatment for these patients involves medical therapy using continuous progestin-based agents. The Levonorgestrel IUD is the preferred method for fertility preservation. Other options include Megestrol or Medroxyprogesterone.

Patients must undergo regular monitoring via endometrial evaluation (hysteroscopy, D&C, or biopsy) every 3–6 months. If a complete response is achieved, the patient may pursue conception, though they must continue surveillance every 6–12 months.

Exam Tip: When evaluating a patient for fertility-sparing options, always check for LVSI and MMR status. The presence of LVSI or MMR deficiency generally contraindicates this approach.

Ovarian Preservation

In certain select cases, ovarian preservation may also be considered for premenopausal patients with Stage IA G1 endometrioid cancer, provided they have normal-appearing ovaries and no high-risk genetic predispositions. Salpingectomy is recommended in these instances.

Summary of Histological Considerations

The management strategy is heavily influenced by the tumor's histology. While endometrioid histology is the most common and often amenable to fertility-sparing protocols, other types require more aggressive approaches:

• Serous Carcinoma: Typically managed as high-grade disease.
• Clear Cell Carcinoma: Requires intensive management.
• Carcinosarcoma: Treated as high-grade disease, often requiring systemic therapy and radiation.

By integrating surgical staging, molecular profiling, and specialized treatment pathways, clinicians can provide highly effective and individualized care for patients with endometrial carcinoma.